MicroVision Applies for Nasdaq Tier Transfer to Extend Compliance Period
Listing At Risk
Company Background
MicroVision is a Redmond, Washington-based developer of lidar-based perception systems targeting automotive, industrial, and security and defense markets, with engineering operations in the U.S. and Germany. The company markets integrated hardware and software solutions and entered 2026 having completed two acquisitions that management says expanded its technology portfolio and engineering capabilities. At roughly $124.9 million in market capitalization, MicroVision remains a small-cap operator in a commercialization-stage lidar sector.
On January 16, 2026, Nasdaq sent MicroVision a deficiency notice informing the company it had failed to maintain the $1.00 minimum bid price required for continued listing on the Nasdaq Global Market under Listing Rule 5450(a)(1). Five months on, the stock has not returned to compliance.
What Was Disclosed
MicroVision submitted an application to transfer its common stock listing from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is subject to review and approval by Nasdaq staff and does not affect the stock's continued trading under the symbol "MVIS." Its purpose is to qualify MicroVision for an additional 180-calendar-day compliance period that is available to Nasdaq Capital Market issuers but would not be available if the company remained on the Global Market.
If the transfer is approved and the additional period granted, the stock must close at $1.00 or above for at least 10 consecutive business days to achieve compliance — with Nasdaq retaining discretion to extend that 10-day window further under Listing Rule 5810(c)(3)(H). MicroVision cautioned that there is no assurance the transfer will be approved, that it will be granted the additional period, or that it will ultimately regain compliance.
Alongside the exchange tier application, MicroVision filed a new Form S-3 shelf registration to replace an expiring one and amended its At-the-Market Issuance Sales Agreement with agents Deutsche Bank Securities Inc., Mizuho Securities USA LLC, and Craig-Hallum Capital Group LLC, updating the agreement to reference the new registration statement. Approximately $42 million of common stock capacity remains unsold under that ATM facility. Separately, a definitive proxy statement already on file with the SEC asks shareholders to authorize the board to effect a reverse stock split — a standard mechanism companies use to cure minimum bid price deficiencies when the stock does not recover organically.
Why It Matters
The Nasdaq Global Market permits a single 180-day cure period from the date of a deficiency notice. That clock began January 16, 2026, and MicroVision exhausted it without resolution. The tier transfer is an affirmative step to access a second 180-day window; companies that exhaust both periods without curing face a formal delisting proceeding.
The decision to renew the ATM facility while the stock trades below $1.00 means any future equity issuances would be made at sharply dilutive prices for most existing shareholders. The reverse stock split authorization request in the proxy provides MicroVision a mechanical backstop if the stock does not recover on its own, though reverse splits do not address the underlying business or financial conditions that drove the stock below compliance thresholds.
CEO Glen DeVos characterized the tier transfer as a "proactive step designed to preserve flexibility" and cited the two 2026 acquisitions and growing customer engagements as evidence of commercial momentum. Whether that progress translates into the sustained market confidence needed to keep shares above $1.00 will determine whether the additional compliance window is sufficient.
